GlassScriptPhysician profile
Lauren E Cline
NPI 1295091056
$2,710.97
in general payments reported to CMS, 2019-2025
26 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $236 · 2021: $490 · 2022: $369 · 2023: $389 · 2024: $349 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.43 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $370.46 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $323.50 | 2019-2025 | |
| Lilly USA, LLC | $246.99 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $217.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $119.76 | 2021-2025 | |
| Eisai INC. | $101.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $95.02 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $91.22 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $78.39 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.79 | 2022 | |
| Esperion Therapeutics, INC. | $68.80 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $64.91 | 2022-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $59.84 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $58.81 | 2021-2025 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $53.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.83 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.24 | 2024-2025 | Caplyta |
| Amgen INC. | $42.78 | 2019-2020 | |
| Dexcom, INC. | $32.56 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.63 | 2025 | Cologuard Collection Kit |
| Ars Pharmaceuticals Operations, INC. | $30.02 | 2025 | Neffy |
| Amarin Pharma, INC. | $20.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.69 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $13.98 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.